Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0G6ZG
|
||||
| Former ID |
DCL000691
|
||||
| Drug Name |
Amediplase
|
||||
| Synonyms |
Amediplase [INN]; Trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Myocardial infarction; Thrombolysis [ICD9: 410, 415.1, 434.91, 459.9; ICD10:I21, I22, I21-I22, I26, I61-I63, I99.9] | Phase 3 | [1], [2] | ||
| Company |
Menarini
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H18O4
|
||||
| Canonical SMILES |
C1=CC=C2C(=C1)C(C(C3=C2C=C4C=CC5=C(C4=C3)C=CC(C5O)O)O)O
|
||||
| InChI |
1S/C22H18O4/c23-19-8-7-13-15(20(19)24)6-5-11-9-17-12-3-1-2-4-14(12)21(25)22(26)18(17)10-16(11)13/h1-10,19-26H/t19-,20-,21-,22-/m0/s1
|
||||
| InChIKey |
YQINXCSNGCDFCQ-CMOCDZPBSA-N
|
||||
| CAS Number |
CAS 151912-11-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
B01AC07
|
||||
| SuperDrug CAS ID |
cas=000058322
|
||||
| Target and Pathway | |||||
| Target(s) | Urokinase-type plasminogen activator | Target Info | Activator | [2] | |
| KEGG Pathway | NF-kappa B signaling pathway | ||||
| Complement and coagulation cascades | |||||
| Transcriptional misregulation in cancer | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| EGFR1 Signaling Pathway | |||||
| PANTHER Pathway | Blood coagulation | ||||
| Plasminogen activating cascade | |||||
| CCKR signaling map ST | |||||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | ||||
| E2F transcription factor network | |||||
| Beta3 integrin cell surface interactions | |||||
| Osteopontin-mediated events | |||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| amb2 Integrin signaling | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| Beta2 integrin cell surface interactions | |||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
| Beta5 beta6 beta7 and beta8 integrin cell surface interactions | |||||
| FGF signaling pathway | |||||
| Reactome | Dissolution of Fibrin Clot | ||||
| WikiPathways | DNA Damage Response (only ATM dependent) | ||||
| Senescence and Autophagy in Cancer | |||||
| Complement and Coagulation Cascades | |||||
| Endochondral Ossification | |||||
| Wnt Signaling Pathway | |||||
| Wnt Signaling Pathway and Pluripotency | |||||
| Blood Clotting Cascade | |||||
| Dissolution of Fibrin Clot | |||||
| Osteopontin Signaling | |||||
| References | |||||
| REF 1 | Amediplase: CGP 42935, K2tu-PA, MEN 9036. BioDrugs. 2002;16(5):378-9. | ||||
| REF 2 | Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.